author-photo

Beata Korytowsky

Pfizer

20

Papers

559

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Beyond metastatic renal cell carcinoma (mRCC) clinical trials: Targeted therapy use and overall survival in community oncology clinics.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Sunitinib objective response (OR) in metastatic renal cell carcinoma (mRCC): Analysis of 1,059 patients treated on clinical trials.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial

2016 Targeted Oncology
Show All
- Source
- Cite
- Save
Citations (29)
Comparison of real-world acute care interventions (ACI) in patients (pts) with advanced non-small cell lung cancer (adv NSCLC) treated with chemotherapy versus targeted therapies.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (64)
Use of “Real-World” data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice

2014 Medical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Methods for adjusting for bias due to crossover in oncology trials.

2014 PharmacoEconomics
Show All
- Source
- Cite
- Save
Citations (30)
Real-World Outcomes in Metastatic Renal Cell Carcinoma: Insights From a Joint Community-Academic Registry

2014 Journal of Oncology Practice
Show All
- Source
- Cite
- Save
Citations (28)
Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial

2014 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (7)